Literature DB >> 2777727

Pharmacokinetics and tissue penetration of cefepime.

K J Nye1, Y G Shi, J M Andrews, R Wise.   

Abstract

The pharmacokinetics of cefepime were studied following a 2 g intravenous infusion, by measuring concentrations in plasma, inflammatory fluid and urine. Mean peak plasma concentrations of 193.1 mg/l were achieved at the end of the 30 min infusion. The mean plasma elimination half-life was 2.1 h. Penetration into inflammatory fluid was rapid, with mean peak levels of 91.5 mg/l occurring 0.9 h after the end of the infusion. Urinary elimination accounted for 98.9% of the dose within 8 h. Therapeutic plasma levels (greater than 2 mg/l) were present for at least 8 h after the end of the infusion, suggesting that twice or three times daily dosing should be sufficient to treat infections due to susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777727     DOI: 10.1093/jac/24.1.23

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.

Authors:  D M Cappelletty
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Meropenem pharmacokinetics and penetration into an inflammatory exudate.

Authors:  R Wise; M Logan; M Cooper; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  Pharmacokinetics and distribution in tissue of FK-037, a new parenteral cephalosporin.

Authors:  R Wise; J M Andrews; P O'Neill; A Jolley; C Fowler; M C Rogge
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  Acute-phase response alters the disposition kinetics of cefepime following intravenous administration to rabbits.

Authors:  A M Abd El-Aty; A Goudah; S M Mouneir; Y E Sunwoo; J H Jang; J G Shin; J H Shim; M Shimoda
Journal:  Vet Res Commun       Date:  2006-12-20       Impact factor: 2.459

5.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 7.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 9.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

10.  Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.

Authors:  J Cronqvist; I Nilsson-Ehle; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.